𝔖 Bobbio Scriptorium
✦   LIBER   ✦

P1-387 Results of a randomized, double-blind, placebo-controlled trial with the neurotrophic compound cerebroylsin in Alzheimer's disease patients

✍ Scribed by Antón Álvarez; Marta Laredo; Carolina Sampedro; Ramón Cacabelos; Verónica Couceiro; Moisés Vargas; Manuel Aleixandre; Elisa Illescas; Carlos Linares; Elias Granizo; Herbert Moessler

Book ID
117413260
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
161 KB
Volume
25
Category
Article
ISSN
0197-4580

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gabapentin in patients with the pruritus
Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial
✍ Nora V. Bergasa; Monnie McGee; Iona H. Ginsburg; Danielle Engler 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB 👁 2 views

Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception. The aim of this double-blind, randomized, placebo-controlled trial was to study the effect of gabapentin on the

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro